How does COCP's PB Ratio compare to its peers?

COCP is good value based on its Price-To-Book Ratio (1.7x) compared to the peer average (8.1x).

How does COCP's PB Ratio compare vs other companies in the US Pharmaceuticals Industry?

COCP is good value based on its Price-To-Book Ratio (1.7x) compared to the US Pharmaceuticals industry average (1.8x).

What is COCP's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

Insufficient data to calculate COCP's Price-To-Book Fair Ratio for valuation analysis.

What is the Fair Price of COCP when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Insufficient data to calculate COCP's fair value for valuation analysis.

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Cocrystal Pharma (Nasdaq:COCP) - Stock Price, News & Analysis

COCP Stock Overview

A biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. More details

COCP fundamental analysis
Snowflake Score
Valuation	1/6
Future Growth	0/6
Past Performance	0/6
Financial Health	4/6
Dividends	0/6

Risk Analysis

Earnings are forecast to decline by an average of 15.1% per year for the next 3 years

Makes less than USD$1m in revenue ($0)

Has less than 1 year of cash runway

Currently unprofitable and not forecast to become profitable over the next 3 years

+ 2 more risks

Cocrystal Pharma, Inc. Competitors

Grace Therapeutics

NasdaqCM:GRCE

US$33.3m

Rani Therapeutics Holdings

NasdaqGM:RANI

US$67.2m

Eyenovia

NasdaqCM:EYEN

US$9.3m

ALT5 Sigma

NasdaqCM:ALTS

US$30.7m

Price History & Performance

Summary of all time highs, changes and price drops for Cocrystal Pharma
Historical stock prices
Current Share Price	US$2.17
52 Week High	US$3.10
52 Week Low	US$1.33
Beta	1.45
11 Month Change	19.89%
3 Month Change	14.81%
1 Year Change	26.90%
33 Year Change	-78.76%
5 Year Change	-63.83%
Change since IPO	-99.11%

Here's Why We're Watching Cocrystal Pharma's (NASDAQ:COCP) Cash Burn Situation

Oct 18

Recent updates

Here's Why We're Watching Cocrystal Pharma's (NASDAQ:COCP) Cash Burn Situation

Oct 18

Cocrystal selects its antiviral drug candidate to develop as a treatment for COVID-19

Oct 11

Cocrystal Pharma GAAP EPS of -$0.25 misses by $0.21

Aug 15

Cocrystal Pharma (NASDAQ:COCP) Is In A Good Position To Deliver On Growth Plans

Aug 14

Cocrystal engages Open Orphan to conduct mid-stage trial of oral influenza drug in UK

Aug 08

We're Not Very Worried About Cocrystal Pharma's (NASDAQ:COCP) Cash Burn Rate

Mar 19

Companies Like Cocrystal Pharma (NASDAQ:COCP) Are In A Position To Invest In Growth

Nov 19

We Think Cocrystal Pharma (NASDAQ:COCP) Can Afford To Drive Business Growth

Aug 06

Cocrystal’s soars 11% as CDI-45205 shows excellent antiviral activity against SARS-CoV-2 and variants

Jun 14

We Think Cocrystal Pharma (NASDAQ:COCP) Needs To Drive Business Growth Carefully

May 05

Cocrystal Pharma updates on COVID-19 antiviral development programs

May 03

Investors Who Bought Cocrystal Pharma (NASDAQ:COCP) Shares A Year Ago Are Now Up 94%

Mar 13

Shareholder Returns

	COCP	US Pharmaceuticals	US Market
7D	4.8%	1.6%	2.2%
1Y	26.9%	9.9%	31.6%

Return vs Industry: COCP exceeded the US Pharmaceuticals industry which returned 9.9% over the past year.

Return vs Market: COCP underperformed the US Market which returned 31.6% over the past year.

Price Volatility

Is COCP's price volatile compared to industry and market?
COCP volatility
COCP Average Weekly Movement	11.6%
Pharmaceuticals Industry Average Movement	9.5%
Market Average Movement	6.3%
10% most volatile stocks in US Market	15.7%
10% least volatile stocks in US Market	3.1%

Stable Share Price: COCP's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: COCP's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

Founded	Employees	CEO	Website
n/a	12	Sam Lee	www.cocrystalpharma.com

Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, norovirus, and respiratory virus infections. The company develops CC-31244, a HCV non-nucleoside polymerase inhibitor that has completed Phase II a clinical trial to treat HCV infection; and CC-42344, a PB2 inhibitor that has completed Phase I clinical trial for treating influenza infection.

Cocrystal Pharma, Inc. Fundamentals Summary

How do Cocrystal Pharma's earnings and revenue compare to its market cap?
COCP fundamental statistics
Market cap	US$22.38m
Earnings (TTM)	-US$18.70m
Revenue (TTM)	n/a

0.0x

P/S Ratio

-1.2x

P/E Ratio

Is COCP overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
COCP income statement (TTM)
Revenue	US$0
Cost of Revenue	US$15.17m
Gross Profit	-US$15.17m
Other Expenses	US$3.53m
Earnings	-US$18.70m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	-1.84
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0%

How did COCP perform over the long term?

See historical performance and comparison

COCP Stock Overview

Risk Analysis

Cocrystal Pharma, Inc. Competitors

NasdaqCM:GRCE

US$33.3m

NasdaqGM:RANI

US$67.2m

NasdaqCM:EYEN

US$9.3m

NasdaqCM:ALTS

US$30.7m

Price History & Performance

Recent News & Updates

New major risk - Financial position

Here's Why We're Watching Cocrystal Pharma's (NASDAQ:COCP) Cash Burn Situation

Price target decreased by 11% to US$8.00

Cocrystal Pharma, Inc. Reports Favorable Results from Single-Ascending Dose Cohorts of Phase 1 Study with CDI-988, its Oral Pan-Viral Norovirus/Coronavirus Protease Inhibitor

Cocrystal Pharma Advances Cc-42344 in Influenza A Phase 2A Study, Expects Topline Results by Late 2024

Cocrystal Pharma, Inc. Announces Completion of Enrollment of 78 Subjects

Recent updates

New major risk - Financial position

Here's Why We're Watching Cocrystal Pharma's (NASDAQ:COCP) Cash Burn Situation

Price target decreased by 11% to US$8.00

Cocrystal Pharma, Inc. Reports Favorable Results from Single-Ascending Dose Cohorts of Phase 1 Study with CDI-988, its Oral Pan-Viral Norovirus/Coronavirus Protease Inhibitor

Cocrystal Pharma Advances Cc-42344 in Influenza A Phase 2A Study, Expects Topline Results by Late 2024

Cocrystal Pharma, Inc. Announces Completion of Enrollment of 78 Subjects

Cocrystal Pharma, Inc. Provides an Update on the Clinical Development of its Novel, Broad-Spectrum Antiviral Investment Candidates

Cocrystal Pharma, Inc. Announces First-Patient-In for Phase 2A Human Challenge Study Evaluating Oral Cc-42344 in Pandemic and Seasonal Influenza A

Cocrystal Pharma, Inc. Highlights Its Novel Inhaled and Oral Influenza A Antiviral Cc-42344 At the World Vaccine Congress West Coast

Cocrystal Pharma, Inc. Doses First Subjects in Clinical Study of CDI-988 for Pandemic Norovirus and Coronavirus

Cocrystal Pharma Reports Highly Favorable Safety and Tolerability Results from a Phase 1 Study with its Oral Antiviral CC-42344 for the Treatment of Pandemic and Seasonal Influenza A

Cocrystal Pharma, Inc. Announces Favorable Safety Data from the Phase 1 Study with Oral Antiviral CC-42344 for the Treatment of Pandemic and Seasonal Influenza A

Cocrystal Pharma, Inc. Announces Enrollment Completed in Phase 1 Influenza A Study with Cocrystal Pharma's Oral Antiviral Candidate Cc-42344

Cocrystal selects its antiviral drug candidate to develop as a treatment for COVID-19

Cocrystal Pharma Announces a 1-for-12 Reverse Stock Split

Consensus forecasts updated

Consensus forecasts updated

Cocrystal Pharma GAAP EPS of -$0.25 misses by $0.21

Cocrystal Pharma (NASDAQ:COCP) Is In A Good Position To Deliver On Growth Plans

Cocrystal Pharma Engages CRO to Conduct Phase 2a Human Challenge Influenza A Clinical Trial with Novel, Broad-Spectrum Antiviral Candidate CC-42344

Cocrystal engages Open Orphan to conduct mid-stage trial of oral influenza drug in UK

Cocrystal Pharma, Inc. Reports CC-42344 Pharmacokinetic Data in Influenza A Once-Daily Dosing

Nasdaq Grants 180 Days to Cocrystal Pharma to Regain Compliance

Price target decreased to US$4.08

Cocrystal Pharma, Inc. Reports Favorable Preliminary Data from Phase 1 Initial Cohorts with Cc-42344, a Novel, Broad-Spectrum Influenza A Antiviral

Cocrystal Pharma, Inc., Annual General Meeting, May 18, 2022

We're Not Very Worried About Cocrystal Pharma's (NASDAQ:COCP) Cash Burn Rate

Price target decreased to US$4.08

Cocrystal Pharma Selects Two Lead Antiviral Drug Candidates for its COVID-19 Oral Drug Program

Cocrystal Pharma Receives FDA Guidance to Advance Clinical Development of its COVID-19 Antiviral CDI-45205

Cocrystal Pharma’s Covid-19 Oral and Intranasal/Pulmonary Protease Inhibitors Exhibit Powerful in Vitro Potency Against the Sars-Cov-2 Omicron Variant

Cocrystal Pharma to Discuss Progress with COVID-19 Antiviral Programs and Clinical Strategy During Noble Capital Markets’ Channelchek Virtual Roadshow

Companies Like Cocrystal Pharma (NASDAQ:COCP) Are In A Position To Invest In Growth

Third quarter 2021 earnings released: US$0.04 loss per share (vs US$0.046 loss in 3Q 2020)

We Think Cocrystal Pharma (NASDAQ:COCP) Can Afford To Drive Business Growth

Cocrystal Pharma, Inc. Completes IND-enabling Studies with CC-42344 for the Treatment of Seasonal and Pandemic Influenza A, Plans to initiate a Phase 1 Trial in the Third Quarter

CocrystalPharma, Inc ’s Lead COVID-19 Antiviral CDI-45205 Shown to be Active Against SARS-CoV-2 and Two Prominent SARS-CoV-2 Variants

Cocrystal’s soars 11% as CDI-45205 shows excellent antiviral activity against SARS-CoV-2 and variants

Co-Founder, Chairman & CEO Gary Wilcox has left the company

Board Member recently sold US$1.7m worth of stock

We Think Cocrystal Pharma (NASDAQ:COCP) Needs To Drive Business Growth Carefully

Cocrystal Pharma, Inc. Provides Update on its COVID-19 Antiviral Discovery and Development Programs

Cocrystal Pharma updates on COVID-19 antiviral development programs

Price target decreased to US$4.50

Full year 2020 earnings released: US$0.17 loss per share (vs US$1.51 loss in FY 2019)

Investors Who Bought Cocrystal Pharma (NASDAQ:COCP) Shares A Year Ago Are Now Up 94%

Cocrystal Pharma, Inc. Extends Drug Discovery Collaboration with HitGen and InterX, Inc

Board Member notifies of intention to sell stock

What Is The Ownership Structure Like For Cocrystal Pharma, Inc. (NASDAQ:COCP)?

Board Member notifies of intention to sell stock

Cocrystal Pharma Provides Summary of Upcoming Presentation at the Reimagine Health Research Symposium

Cocrystal Pharma Announces Further Development of Influenza A/B Antiviral Compounds by Merck Under Exclusive Worldwide License and Collaboration Agreement

New 90-day high: US$2.19

Cocrystal sees 2021 cash burn of $800k a month

Cocrystal Pharma to test CDI-45205 against coronaviruses

Is Cocrystal Pharma (NASDAQ:COCP) In A Good Position To Invest In Growth?

New 90-day high: US$1.71

Third quarter 2020 earnings released: US$0.046 loss per share

New 90-day low: US$0.84

Cocrystal Pharma, Inc. Provides Update on Influenza A Program